세계의 분지병변 시장 : 시장 규모, 쉐어, 동향 분석(용도별, 지역별), 부문별 예측(2025-2030년)

Bifurcation Lesions Market Size, Share & Trends Analysis Report, By Application (Coronary, Peripheral), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,266,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,655,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,434,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

분지병변 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 분지병변 시장 규모는 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 6.0%를 기록하며, 2030년까지 35억 달러에 이를 전망입니다.

기술 개발과 상환을 위한 지원적인 정부 이니셔티브는 예측 기간 동안 시장을 견인할 가능성이 높습니다.

노인 인구 증가와 건강에 해로운 라이프 스타일은 심혈관 장애의 발생률 증가의 원인이 되었습니다. 게다가 혁신적인 디바이스의 승인 및 상용화 증가나 향후 수년간에 분지병변의 치료를 위한 새로운 디바이스의 진입이 전망되는 것도 시장을 견인할 가능성이 높습니다.

또한 저렴한 가격 상승, 낮은 침습 수술 수요 증가, 의료 투어리즘 증가 등의 요인도 전 세계적으로 분지병변 수술 수요를 밀어 올리고 있습니다. 다양한 조사에 따르면 관상동맥 분지병변에 대한 치료는 경피적 관상동맥 인터벤션 전체의 약 20%를 차지하고 있습니다.

분지병변 시장 : 분석 개요

• 분지병변용 디바이스의 상용화 증가나 업계 각사에 의한 연구개발에 대한 투자가 시장을 밀어 올리는 요인이 되어 그 결과 2025년부터 2030년까지 CAGR은 약 6.0%로 예상됩니다.
• 관상동맥 혈관 부문은 심장의 복잡한 혈관망의 존재, 장치의 가용성 증가, 분기 병변에 대한 수술적 개입에 대한 의식이 증가함에 따라 2024년 시장의 최대 점유율을 차지했습니다.
• 말초 혈관 부문은 말초 용도용 디바이스 개발을 위한 업계 기업의 투자 증가와 플라크의 정확한 검출을 용이하게 하는 진단의 진보에 의해 향후 수년간에 유리한 성장을 나타낼 가능성이 높습니다.
• 지역별로는 북미가 2024년 분지병변 시장에서 가장 큰 점유율을 차지하고 있습니다. 약물용출 스텐트 수요 증가, 분지병변용 디바이스의 상용화, 주요 기업의 현지 진출 등으로 앞으로도 우위를 유지할 것으로 예측되고 있습니다.
• 아시아태평양은 의료 인프라 개선, 의료 투어리즘, 이 지역 시장 진출 기업에 의한 투자 증가로 향후 10년간 가장 급속한 성장이 예상되고 있습니다.
• 이 시장의 주요 기업으로는 Abbott, Boston Scientific Corporation, Cardinal Health, Medtronic, Johnson & Johnson Services, Inc., C. R. Bard, Inc., Spectranetics, and Terumo Medical Corporation 등을 들 수 있습니다. Tryton Medical, Inc.은 풍선 확장 가능한 단선 스텐트 전달 시스템을 갖춘 Tryton Side Branch Stent를 개발하여 분기 병변의 치료를 위해 측지 동맥에 유치 할 수 있게 했습니다. 이 스텐트는 미국, 유럽, 중동 및 아프리카에서 판매됩니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 분지병변 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 분지병변 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 분지병변 시장 : 용도별 추정·동향 분석

• 분지병변 시장 : 용도별 대시보드
• 분지병변 시장 : 용도별 변동 분석
• 분지병변 시장 : 시장 규모의 예측과 동향 분석, 용도별(2018-2030년)
• 관상동맥
• 말초 혈관

제5장 분지병변 시장 : 지역별 추정·동향 분석(용도별, 지역별)

• 세계의 분지병변 시장 : 지역별 대시보드
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 노르웨이
  • 덴마크
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 사우디아라비아
  • 남아프리카
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 최신 동향과 영향 분석 : 주요 제조업체별
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 유통업체·채널 파트너 목록
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2023년)
  • Boston Scientific Corp.
  • Abbott
  • Cardinal Health
  • Medtronic
  • CR Bard, Inc.
  • Johnson &Johnson Services, Inc.
  • Spectranetics
  • Terumo Medical Corp.
  • Tryton Medical Inc.

JHS

영문 목차

영문목차

Bifurcation Lesions Market Growth & Trends:

The global bifurcation lesions market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological developments and supportive government initiatives for reimbursement are likely to drive the market during the forecast period.

The increasing geriatric population and unhealthy lifestyle are responsible for growth in the incidence of cardiovascular disorders. Furthermore, an increase in approval & commercialization of innovative devices and the expected entry of new devices for the treatment of bifurcation lesions in the coming years are likely to drive the market.

In addition, factors such as rising affordability, increase in demand for minimally invasive procedures, and growing medical tourism are also boosting demand for bifurcation lesions procedures across the globe. According to various studies, procedures for coronary bifurcation lesions comprise approximately 20% of total percutaneous coronary interventions.

Bifurcation Lesions Market Report Highlights:

• Increase in the commercialization of devices for bifurcation lesions and investments by industry players for R&D are the factors expected to boost the market, resulting in an anticipated CAGR of around 6.0% from 2025 to 2030
• The coronary vascular segment accounted for the maximum share of the market in 2024 due to the presence of complex vascular network in heart, increased availability of devices, and rise in awareness regarding surgical interventions for bifurcation lesions.
• The peripheral vascular segment is likely to witness lucrative growth in the coming years due to an increase in investments by industry players for the development of devices for peripheral application and advancements in diagnostics facilitating accurate detection of plaque.
• Geographically, North America held the largest share of the bifurcation lesions market in 2024. It is anticipated to maintain its dominance in the coming years due to increasing demand for drug-eluting stents, commercialization of devices for bifurcation lesions, and the local presence of major market players.
• The Asia Pacific is expected to observe the fastest growth over the next decade owing to improvement in healthcare infrastructure, medical tourism, and a rise in investments by market players in the region.
• Some of the key players in the market are Abbott; Boston Scientific Corporation; Cardinal Health; Medtronic; Johnson & Johnson Services, Inc.; C. R. Bard, Inc.; Spectranetics; and Terumo Medical Corporation. Tryton Medical, Inc. developed the Tryton Side Branch Stent with a balloon-expandable, single-wire stent delivery system that can be deployed in the side branch artery for treatment of bifurcation lesions. The device is available in the U.S. and Europe as well as Middle East & Africa.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application Segment
  • 2.2.2. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Bifurcation Lesions Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of congenital heart disease
    • 3.2.1.2. Increasing number of CVD incidence
    • 3.2.1.3. Increasing awareness among the population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Limited awareness and adoption
• 3.3. Bifurcation Lesions Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Bifurcation Lesions Market: Application Estimates & Trend Analysis

• 4.1. Bifurcation Lesions Market: Application Dashboard
• 4.2. Bifurcation Lesions Market: Application Movement Analysis
• 4.3. Bifurcation Lesions Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. Coronary
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Peripheral
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Bifurcation Lesions Market: Regional Estimates & Trend Analysis by Application, and Region

• 5.1. Global Bifurcation Lesions Market: Regional Dashboard
• 5.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 5.3. North America
  • 5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key country dynamics
    • 5.3.4.2. Regulatory framework/ reimbursement structure
    • 5.3.4.3. Competitive scenario
    • 5.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.2. UK
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.3. Germany
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.4. France
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.5. Italy
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.6. Spain
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.9. Denmark
    • 5.4.9.1. Key country dynamics
    • 5.4.9.2. Regulatory framework/ reimbursement structure
    • 5.4.9.3. Competitive scenario
    • 5.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.3. Japan
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.4. India
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.5. Australia
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.7. South Korea
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework/ reimbursement structure
    • 5.5.7.3. Competitive scenario
    • 5.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Brazil
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7.3. South Africa
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7.4. UAE
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7.5. Kuwait
    • 5.7.5.1. Key country dynamics
    • 5.7.5.2. Regulatory framework/ reimbursement structure
    • 5.7.5.3. Competitive scenario
    • 5.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. List of key distributors and channel partners
  • 6.3.2. Key customers
  • 6.3.3. Key company market share analysis, 2023
  • 6.3.4. Boston Scientific Corp.
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Abbott
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Cardinal Health
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Medtronic
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. C. R. Bard, Inc.
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Johnson & Johnson Services, Inc.
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Spectranetics
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Terumo Medical Corp.
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Product benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. Tryton Medical Inc.
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Product benchmarking
    • 6.3.12.4. Strategic initiatives

관련자료